成人患者阿哌沙班与利伐沙班的峰浓度和谷浓度:系统综述与荟萃分析
该系统综述与荟萃分析检索截至2023年10月的观察性研究,汇总16项研究共1054例阿哌沙班和1321例利伐沙班患者的峰谷浓度,并按剂量分层报告均值及95%CI。Meta回归显示年龄和肌酐清除率与阿哌沙班峰浓度相关,肌酐清除率与两药谷浓度相关。汇总均值与不同药代动力学研究报告的预期浓度范围一致。
要点
- 阿哌沙班5 mg峰浓度228 ng/mL(95%CI 204-252),谷浓度113 ng/mL(95%CI 101-124)。
- 利伐沙班20 mg峰浓度229 ng/mL(95%CI 193-264),谷浓度36 ng/mL(95%CI 25-47)。
- 年龄和肌酐清除率与阿哌沙班峰浓度相关,肌酐清除率与两药谷浓度相关。
核心结论
- 阿哌沙班与利伐沙班的汇总平均浓度与不同药代动力学研究报告的预期浓度范围一致。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus和Web of Science截至2023年10月的观察性研究。
- 共纳入16项研究,汇总阿哌沙班患者1054例和利伐沙班患者1321例,采用随机效应模型。
- 使用Meta回归分析影响药物浓度的因素。
主要发现
- 阿哌沙班2.5 mg峰浓度157 ng/mL(95%CI 127-187),谷浓度77 ng/mL(95%CI 56-98)。
- 阿哌沙班5 mg峰浓度228 ng/mL(95%CI 204-252),谷浓度113 ng/mL(95%CI 101-124)。
- 利伐沙班10 mg峰浓度168 ng/mL(95%CI 104-232),谷浓度23 ng/mL(95%CI 13-32)。
- 利伐沙班15 mg峰浓度225 ng/mL(95%CI 192-257),谷浓度31 ng/mL(95%CI 26-36)。
- 利伐沙班20 mg峰浓度229 ng/mL(95%CI 193-264),谷浓度36 ng/mL(95%CI 25-47)。
关键数值与推荐
- Meta回归显示年龄和肌酐清除率与阿哌沙班峰浓度相关。
- 肌酐清除率与阿哌沙班和利伐沙班的谷浓度相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apixaban and rivaroxaban are activated factor X (FXa) inhibitors commonly used for treatment of venous thromboembolism and stroke prevention in patients with atrial fibrillation. While routine monitoring of their concentrations is not recommended, but it may be beneficial in certain situations. Expected peak and trough concentrations remain poorly understood, with most data derived from small studies. OBJECTIVES: To establish the average peak and trough concentrations of apixaban and rivaroxaban from real-world studies. METHODS: PubMed, Scopus, and Web of Science were searched until October 2023 for observational studies reporting apixaban and rivaroxaban concentrations. Meta-regression was used to examine factors influencing these concentrations. RESULTS: Sixteen studies involving 1054 apixaban and 1321 rivaroxaban patients were pooled using random-effects model. Mean apixaban peak concentrations were 157 ng/mL (95% CI, 127-187) for 2.5 mg and 228 ng/mL (95% CI, 204-252) for 5 mg, with trough concentrations of 77 ng/mL (95% CI, 56-98) and 113 ng/mL (95% CI, 101-124), respectively. Mean rivaroxaban peak concentrations were 168 ng/mL (95% CI, 104-232) for 10 mg, 225 ng/mL (95% CI, 192-257) for 15 mg, and 229 ng/mL (95% CI, 193-264) for 20 mg, with trough concentrations of 23 ng/mL (95% CI, 13-32), 31 ng/mL (95% CI, 26-36), and 36 ng/mL (95% CI, 25-47), respectively. Meta-regression revealed age and creatinine clearance correlated with apixaban peak concentrations. Creatinine clearance correlated with apixaban and rivaroxaban trough concentrations. CONCLUSION: The pooled mean concentrations align with expected concentration ranges reported in different pharmacokinetic studies.
引用
- Almalbis CA, Md Redzuan A, Andrada CP, et al. Peak and trough concentrations of apixaban and rivaroxaban in adult patients: a systematic review and meta-analysis. J Thromb Haemost. 2025. PMID: 39798921. doi:10.1016/j.jtha.2024.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。